A multicenter trial assessed the Spiration Valve System (SVS) against standard medical care for treating severe emphysema in patients aged 40 and older.
The study found that the SVS led to significant improvements in lung function (FEV) and other health measures after 6 and 12 months, although it increased the risk of serious adverse events, particularly pneumothorax.
Overall, while SVS showed effective results for managing severe emphysema, the safety concerns highlighted the need for careful patient monitoring.